Key Highlights

  • Net Revenue was USD 37.1 million, down 22% from USD 47.6 million.
  • Adjusted EBITDA was USD 1.9 million, or 5.2% of revenue.
  • The company held USD 13.7 million of cash and no debt.
  • The fiscal year aligns with the calendar year from January 1, 2027.

LifeVantage Corporation (NASDAQ:LFVN) reported net revenue of USD 37.1 million for the quarter ended September 30, 2026, its first quarter of fiscal year 2027, down 22% from USD 47.6 million a year earlier. Reported EPS was USD 0.05 and revenue was USD 37.12 million, compared with estimates of EPS of USD 0.06 and revenue of USD 40.49 million.

The company said the decline was driven by continued downward pressure in orders from its active consumer base and lower average order size, reflecting the broader macroeconomic environment and lower sales from the MindBody GLP-1 System, partially offset by sales of the LoveBiome product line acquired in October 2025. Foreign currency reduced revenue by USD 400 thousand.

Regional and Margin Detail

Revenue in the Americas decreased 22.2% to USD 29 million. Revenue in Asia Pacific and Europe decreased 21.2% to USD 8.2 million, including a USD 400 thousand negative foreign currency impact.

Gross profit was 75.4% of revenue, compared with 79.5%, reflecting higher inventory obsolescence expenses along with higher shipping and Warehouse expenses. Excluding the additional inventory allowance related to the MindBody product line, adjusted Gross Profit was 78.2%. Commissions and incentive expense was 41.4% of revenue, compared with 43.5%, and selling, general and administrative expenses were 34.3%, compared with 31.2%.

Earnings and Balance Sheet

GAAP operating loss was USD 100 thousand, compared with Operating Income of USD 2.3 million. Adjusted non-GAAP operating income was USD 900 thousand, compared with USD 2.5 million. GAAP net loss was USD 200 thousand, or USD 0.02 per diluted share, compared with Net Income of USD 2.2 million, or USD 0.17. Adjusted non-GAAP net income was USD 600 thousand, or USD 0.05 per share, compared with USD 2.3 million, or USD 0.18.

Adjusted EBITDA was USD 1.9 million, or 5.2% of revenue, compared with USD 3.9 million, or 8.2%. Income tax expense was USD 12 thousand.

The company ended the quarter with USD 13.7 million of cash and no debt, compared with USD 14.9 million of cash at June 30, 2026. Cash from operations was USD 500 thousand, compared with USD 2.3 million used in operations a year earlier. A USD 5 million revolving line of Credit had no balance outstanding. Capital expenditures were USD 1.2 million, compared with USD 400 thousand, tied to Investment in a new E-commerce platform. The company did not repurchase shares in the quarter.

Strategic Roadmap

The chief executive, who said he has been with the company for just over 90 days, described a comprehensive strategy covering the go to market approach, Marketing engine, competitive proposition and cost structure. It starts with a new campaign built on research on how the lead product Protandim NRF2 activates the body's natural defense system against environmental toxins.

The company plans to launch a new website and digital platform in North America in the second quarter of calendar 2027, followed by a new Business suite for sellers in the third quarter of 2027. Starting January 1, 2027, the fiscal year aligns with the calendar year, with an effective tax rate of approximately 20% to 25% cited for the six month transition period ending December 31, 2026.

Items Cited on the Call

Disclosed reference points include the order and average order size trends, the inventory allowance related to MindBody and the transition period timing.